...
首页> 外文期刊>Oncology letters >miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-alpha in glioblastoma
【24h】

miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-alpha in glioblastoma

机译:miR-204通过降解胶质母细胞瘤中的FAP-α来逆转替莫唑瘤抗性并抑制癌症发起细胞表型

获取原文
获取原文并翻译 | 示例
           

摘要

Malignant gliomas are treated with temozolomide (TMZ) at present, but often exhibit resistance to this agent. Cancer-initiating cells (CICs) have been suggested to lead to TMZ resistance. The mechanisms underlying CICs-based TMZ resistance are not fully understood. MicroRNAs (miRNAs) have been demonstrated to serve important roles in tumorigenesis and TMZ resistance. In the present study, a sphere forming assay and western blot analysis were performed to detect the formation of CICs and fibroblast activation protein alpha (FAP-alpha) protein expression. It was revealed that TMZ resistance promoted the formation of CICs and upregulated FAP-alpha expression in glioblastoma cells. Over-expressing FAP-alpha was also demonstrated to promote TMZ resistance and induce the formation of CICs in U251MG cells. In addition, using a reverse transcription-quantitative polymerase chain reaction, it was observed that miR-204 was downregulated in U251MG-resistant (-R) cells. miR-204 expression negatively correlated with the FAP-alpha levels in human glioblastoma tissues, and it may inhibit the formation of CICs and reverse TMZ resistance in U251MG-R cells. Therefore, it was concluded that miR-204 reversed temozolomide resistance and inhibited CICs phenotypes by degrading FAP-alpha in glioblastoma.
机译:目前用替代唑啉代(TMZ)处理恶性胶质瘤,但通常表现出对该试剂的耐药性。已经提出癌症引发细胞(CICS)导致TMZ抗性。基于CICS的TMZ抗性的机制尚不完全理解。已经证明MicroRNA(miRNA)在肿瘤发生和TMZ抗性中提供重要作用。在本研究中,进行球形形成测定和蛋白质印迹分析以检测CICS和成纤维细胞活化蛋白α(FAP-α)蛋白表达的形成。揭示了TMZ抗性促进了胶质母细胞瘤细胞中的CICS和上调的FAP-α表达。还证明了过度表达的FAP-α以促进TMZ抗性并诱导U251MG细胞中的CICS形成。另外,使用逆转录定量聚合酶链反应,观察到MIR-204在U251mg抗性(-R)细胞中下调。 miR-204表达与人胶质母细胞瘤组织中的FAP-α水平负相关,并且它可能抑制U251MG-R细胞中的CICS和反向TMZ抗性的形成。因此,得出结论,MiR-204通过降解胶质母细胞瘤中的FAP-α逆转替莫唑胺抗性和抑制CICS表型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号